Cascadian Therapeutics, Inc.

Biotechnology, Biotechnology
Founded in 1985
Seattle, Washington
http://www.cascadianrx.com
None

About Cascadian Therapeutics, Inc.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our most advanced product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor. We are headquartered in Seattle, Washington. For more information, visit www.cascadianrx.com.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 84.4M None
  • Last Funding: 47M None (None)
  • Funding Status: None

Technology Stack

Cascadian Therapeutics, Inc. actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Biotechnology

Headquarters: Seattle, Washington